Raras
Buscar doenças, sintomas, genes...
Fibrose cística
ORPHA:586CID-10 · E84.0CID-11 · CA25OMIM 219700PCDT · SUSDOENÇA RARA

Fibrose cística (FC) é uma doença genética caracterizada pela produção de suor com muito sal e de muco (catarro) mais grosso e pegajoso que o normal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Fibrose cística (FC) é uma doença genética caracterizada pela produção de suor com muito sal e de muco (catarro) mais grosso e pegajoso que o normal.

Pesquisas ativas
30 ensaios
1738 total registrados no ClinicalTrials.gov
Publicações científicas
56.615 artigos
Último publicado: 2026 Apr 1
Medicamentos
4 registrados
LUMACAFTOR, IVACAFTOR, TEZACAFTOR

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
LUMACAFTORIVACAFTORTEZACAFTORATALUREN

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
11.1319
Europe
Início
All ages
🏥
SUS: Cobertura completaScore: 80%
PCDT disponível6 medicamentos CEAFTriagem neonatal (Fase 1)CID-10: E84.0
🇧🇷Dados SUS / DATASUS2024
3.245
internações/ano
R$ 8.920
custo médio/internação
ESTADOS COM MAIS INTERNAÇÕES
SPRSPRMGRJ
PROCEDIMENTOS SIGTAP (1)
0202080013
Teste do pezinho (triagem neonatal)newborn_screening
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
11 sintomas
🫁
Pulmão
10 sintomas
🛡️
Imunológico
4 sintomas
🦴
Ossos e articulações
4 sintomas
📏
Crescimento
2 sintomas
🧠
Neurológico
2 sintomas

+ 19 sintomas em outras categorias

Características mais comuns

100%prev.
Cloreto elevado no suor
Muito frequente (99-80%)
95%prev.
Bronquiectasia
Muito frequente (99-80%)
90%prev.
Obstrução das vias aéreas
Muito frequente (99-80%)
90%prev.
Infecções respiratórias recorrentes
Muito frequente (99-80%)
90%prev.
Má absorção
Muito frequente (99-80%)
90%prev.
Ducto deferente ausente
Muito frequente (99-80%)
56sintomas
Muito frequente (7)
Frequente (9)
Ocasional (24)
Muito raro (10)
Sem dados (6)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 56 características clínicas mais associadas, ordenadas por frequência.

Cloreto elevado no suorElevated sweat chloride
Muito frequente (99-80%)100%
BronquiectasiaBronchiectasis
Muito frequente (99-80%)95%
Obstrução das vias aéreasAirway obstruction
Muito frequente (99-80%)90%
Infecções respiratórias recorrentesRecurrent respiratory infections
Muito frequente (99-80%)90%
Má absorçãoMalabsorption
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico56.615PubMed
Últimos 10 anos200publicações
Pico2026199 papers
Linha do tempo
2026Hoje · 2026🧪 1988Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: IRT (Tripsina Imunorreativa) em sangue seco
Fase 1 do PNTNTriagem nacionalimplemented_nationally
Incidência no Brasil: 1:7.500

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

20 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

SLC6A14Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)Modifying germline mutation inRestrito
FUNÇÃO

Amino acid transporter that plays an important role in the absorption of amino acids in the intestinal tract. Mediates the uptake of a broad range of neutral and cationic amino acids (with the exception of proline) in a Na(+)/Cl(-)-dependent manner (PubMed:10446133). Transports non-alpha-amino acids such as beta-alanine with low affinity, and has a higher affinity for dipolar and cationic amino acids such as leucine and lysine (PubMed:18599538). Can also transport carnitine, butirylcarnitine and

LOCALIZAÇÃO

MembraneApical cell membrane

VIAS BIOLÓGICAS (2)
Amino acid transport across the plasma membraneSLC-mediated transport of neurotransmitters
EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
29.6 TPM
Pulmão
8.8 TPM
Skin Sun Exposed Lower leg
5.5 TPM
Skin Not Sun Exposed Suprapubic
4.1 TPM
Vagina
3.7 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:11047UniProt:Q9UN76
FCGR2ALow affinity immunoglobulin gamma Fc region receptor II-aCandidate gene tested inTolerante
FUNÇÃO

Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
FCGR activationNeutrophil degranulation
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
342.9 TPM
Pulmão
57.9 TPM
Baço
57.1 TPM
Aorta
30.2 TPM
Adipose Visceral Omentum
29.2 TPM
OUTRAS DOENÇAS (3)
malaria, susceptibility tosystemic lupus erythematosuscystic fibrosis
HGNC:HGNC:3616UniProt:P12318
SLC11A1Natural resistance-associated macrophage protein 1Modifying germline mutation inTolerante
FUNÇÃO

Macrophage-specific antiporter that fluxes metal ions in either direction against a proton gradient. Localized to late endosomal lysosomal membranes, delivers bivalent cations from the cytosol into these acidic compartments where they may directly affect antimicrobial activity (PubMed:11237855). Involved in iron metabolism and host natural resistance to infection with intracellular parasites. Pathogen resistance involves sequestration of Fe(2+) and Mn(2+), cofactors of both prokaryotic and eukar

LOCALIZAÇÃO

Late endosome membraneLysosome membrane

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
495.5 TPM
Pulmão
253.4 TPM
Baço
165.8 TPM
Adipose Visceral Omentum
26.6 TPM
Fallopian Tube
24.0 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (4)
cystic fibrosistuberculosisMycobacterium tuberculosis, susceptibilityBuruli ulcer, susceptibility to
HGNC:10907UniProt:P49279
TGFB1Transforming growth factor beta-1 proproteinModifying germline mutation inModerado
FUNÇÃO

Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix (PubMed:28117447). Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with 'milieu molecules',

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixSecreted

VIAS BIOLÓGICAS (10)
TGF-beta receptor signaling activates SMADsDownregulation of TGF-beta receptor signalingUCH proteinasesTGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)TGFBR1 LBD Mutants in Cancer
MECANISMO DE DOENÇA

Camurati-Engelmann disease

An autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
306.4 TPM
Aorta
192.6 TPM
Baço
156.1 TPM
Linfócitos
155.3 TPM
Pulmão
133.8 TPM
OUTRAS DOENÇAS (3)
inflammatory bowel disease, immunodeficiency, and encephalopathyCamurati-Engelmann diseasecystic fibrosis
HGNC:11766UniProt:P01137
EDNRAEndothelin-1 receptorModifying germline mutation inAltamente restrito
FUNÇÃO

Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsPeptide ligand-binding receptors
MECANISMO DE DOENÇA

Mandibulofacial dysostosis with alopecia

A form of mandibulofacial dysostosis, a disorder characterized by malar and mandibular hypoplasia, typically associated with abnormalities of the ears and eyelids. MFDA features include maxillary dysmorphism with dysplastic zygomatic arch, hypoplastic mandible, scalp alopecia, scant eyebrows and eyelashes, severe hypoplasia or aplasia of eyelids, small cupped dysplastic ears, conductive hearing loss, cleft palate, dental anomalies, micrognathia, and limited jaw mobility.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
89.7 TPM
Cervix Endocervix
82.2 TPM
Útero
55.6 TPM
Ovário
50.4 TPM
Fallopian Tube
43.7 TPM
OUTRAS DOENÇAS (3)
mandibulofacial dysostosis with alopeciacystic fibrosismigraine with or without aura, susceptibility to, 1
HGNC:3179UniProt:P25101
MIFAnti-Muellerian hormoneModifying germline mutation inTolerante
FUNÇÃO

The anti-Muellerian hormone (AMH) plays an important role in several reproductive functions (PubMed:14742691, PubMed:34155118, PubMed:3754790, PubMed:8469238). Anti-Muellerian hormone binds and activates AMHR2, its specific type-II receptor, that heterodimerizes with type-I receptors (ACVR1 and BMPR1A) to regulate target gene expression through downstream SMAD protein signal transduction (PubMed:20861221, PubMed:34155118). Produced and secreted by Sertoli cells of the male fetus, anti-Muellerian

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Cell surface interactions at the vascular wallNeutrophil degranulation
MECANISMO DE DOENÇA

Persistent Muellerian duct syndrome 1

A form of male pseudohermaphroditism characterized by a failure of Muellerian duct regression in otherwise normal males.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
29.1 TPM
Cerebelo
21.8 TPM
Cérebro - Hemisfério cerebelar
20.5 TPM
Córtex cerebral
5.6 TPM
Próstata
5.6 TPM
OUTRAS DOENÇAS (3)
systemic-onset juvenile idiopathic arthritiscystic fibrosisjuvenile idiopathic arthritis
HGNC:7097UniProt:P03971
STX1ASyntaxin-1AModifying germline mutation inAltamente restrito
FUNÇÃO

Plays an essential role in hormone and neurotransmitter calcium-dependent exocytosis and endocytosis (PubMed:26635000). Part of the SNARE (Soluble NSF Attachment Receptor) complex composed of SNAP25, STX1A and VAMP2 which mediates the fusion of synaptic vesicles with the presynaptic plasma membrane. STX1A and SNAP25 are localized on the plasma membrane while VAMP2 resides in synaptic vesicles. The pairing of the three SNAREs from the N-terminal SNARE motifs to the C-terminal anchors leads to the

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneSynapse, synaptosomeCell membraneSecreted

VIAS BIOLÓGICAS (10)
Serotonin Neurotransmitter Release CycleGABA synthesis, release, reuptake and degradationGlutamate Neurotransmitter Release CycleNorepinephrine Neurotransmitter Release CycleAcetylcholine Neurotransmitter Release Cycle
EXPRESSÃO TECIDUAL(Ubíquo)
Córtex cerebral
157.9 TPM
Brain Frontal Cortex BA9
155.5 TPM
Cérebro - Hemisfério cerebelar
139.0 TPM
Cerebelo
137.6 TPM
Pituitária
121.0 TPM
OUTRAS DOENÇAS (2)
cystic fibrosisWilliams syndrome
HGNC:11433UniProt:Q16623
GSTM3Glutathione S-transferase Mu 3Modifying germline mutation inTolerante
FUNÇÃO

Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May govern uptake and detoxification of both endogenous compounds and xenobiotics at the testis and brain blood barriers

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Glutathione conjugation
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
275.9 TPM
Ovário
98.1 TPM
Rim - Medula
52.7 TPM
Nervo tibial
45.4 TPM
Brain Nucleus accumbens basal ganglia
44.0 TPM
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:4635UniProt:P21266
KCNN4Intermediate conductance calcium-activated potassium channel protein 4Modifying germline mutation inTolerante
FUNÇÃO

Intermediate conductance calcium-activated potassium channel that mediates the voltage-independent transmembrane transfer of potassium across the cell membrane through a constitutive interaction with calmodulin which binds the intracellular calcium allowing its opening (PubMed:10026195, PubMed:10961988, PubMed:11425865, PubMed:15831468, PubMed:17157250, PubMed:18796614, PubMed:26148990, PubMed:9326665, PubMed:9380751, PubMed:9407042). The current is characterized by a voltage-independent activat

LOCALIZAÇÃO

Cell membraneCell projection, ruffle membrane

VIAS BIOLÓGICAS (1)
Ca2+ activated K+ channels
MECANISMO DE DOENÇA

Dehydrated hereditary stomatocytosis 2

An autosomal dominant hemolytic anemia characterized by primary erythrocyte dehydration. Erythrocytes exhibit decreased total cation and potassium content that are not accompanied by a proportional net gain of sodium and water. Affected individuals typically manifest mild to moderate compensated hemolytic anemia, with an increased erythrocyte mean corpuscular hemoglobin concentration and a decreased osmotic fragility, both of which reflect cellular dehydration. Their red cells exhibit a panel of various shape abnormalities such as elliptocytes, hemighosts, schizocytes, and very rare stomatocytic cells. Complications such as splenomegaly and cholelithiasis, resulting from increased red cell trapping in the spleen and elevated bilirubin levels, respectively, may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula salivar
115.7 TPM
Linfócitos
53.8 TPM
Skin Sun Exposed Lower leg
34.3 TPM
Próstata
31.7 TPM
Baço
25.2 TPM
OUTRAS DOENÇAS (3)
dehydrated hereditary stomatocytosis 2cystic fibrosisdehydrated hereditary stomatocytosis
HGNC:6293UniProt:O15554
CFTRCystic fibrosis transmembrane conductance regulatorDisease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis (PubMed:26823428). Mediates the transport of chloride ions across the cell membrane (PubMed:10792060, PubMed:11524016, PubMed:11707463, PubMed:12519745, PubMed:12529365, PubMed:12588899, PubMed:12727866, PubMed:15010471, PubMed:17036051, PubMed:1712898, PubMed:17182731, PubMed:19398555, PubMed:19621064, PubMed:22178883, PubMed:25330774, PubMed:26846474, PubMed:2808770

LOCALIZAÇÃO

Apical cell membraneEarly endosome membraneCell membraneRecycling endosome membraneEndoplasmic reticulum membraneNucleus

VIAS BIOLÓGICAS (1)
ABC-family proteins mediated transport
MECANISMO DE DOENÇA

Cystic fibrosis

A common generalized disorder of the exocrine glands which impairs clearance of secretions in a variety of organs. It is characterized by the triad of chronic bronchopulmonary disease (with recurrent respiratory infections), pancreatic insufficiency (which leads to malabsorption and growth retardation) and elevated sweat electrolytes. It is the most common genetic disease in Caucasians, with a prevalence of about 1 in 2'000 live births. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (8)
cystic fibrosiscongenital bilateral aplasia of vas deferens from CFTR mutationaquagenic palmoplantar keratodermacongenital bilateral absence of vas deferens
HGNC:1884UniProt:P13569
CLCA4Calcium-activated chloride channel regulator 4Modifying germline mutation inTolerante
FUNÇÃO

May be involved in mediating calcium-activated chloride conductance

LOCALIZAÇÃO

Cell membraneApical cell membraneSecreted

VIAS BIOLÓGICAS (1)
Stimuli-sensing channels
VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:2018UniProt:Q14CN2
GCLCGlutamate--cysteine ligase catalytic subunitModifying germline mutation inAltamente restrito
FUNÇÃO

Catalyzes the ATP-dependent ligation of L-glutamate and L-cysteine and participates in the first and rate-limiting step in glutathione biosynthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
NFE2L2 regulating anti-oxidant/detoxification enzymesGlutathione synthesis and recycling
MECANISMO DE DOENÇA

Anemia, congenital, non-spherocytic hemolytic, 7

An autosomal recessive disease characterized by hemolytic anemia, glutathione deficiency, myopathy, late-onset spinocerebellar degeneration, and peripheral neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Bladder
33.0 TPM
Baço
27.6 TPM
Vagina
26.2 TPM
Esôfago - Mucosa
25.6 TPM
Fígado
25.6 TPM
OUTRAS DOENÇAS (3)
gamma-glutamylcysteine synthetase deficiencycystic fibrosismyocardial infarction, susceptibility to
HGNC:4311UniProt:P48506
HFEHereditary hemochromatosis proteinModifying germline mutation inTolerante
FUNÇÃO

Binds to transferrin receptor (TFR) and reduces its affinity for iron-loaded transferrin

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Transferrin endocytosis and recycling
MECANISMO DE DOENÇA

Hemochromatosis 1

A disorder of iron metabolism characterized by iron overload. Excess iron is deposited in a variety of organs leading to their failure, and resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis, and hypogonadotropic hypogonadism. Severe effects of the disease usually do not appear until after decades of progressive iron loading.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
15.7 TPM
Glândula adrenal
8.8 TPM
Baço
7.8 TPM
Aorta
6.6 TPM
Cervix Endocervix
6.5 TPM
OUTRAS DOENÇAS (6)
hemochromatosis type 1sporadic porphyria cutanea tardafamilial porphyria cutanea tardaobsolete symptomatic form of hemochromatosis type 1
HGNC:4886UniProt:Q30201
SLC26A9Solute carrier family 26 member 9Modifying germline mutation inTolerante
FUNÇÃO

Ion transporter that can act both as an ion channel and anion exchanger (PubMed:15800055, PubMed:17673510, PubMed:26801567, PubMed:32818062). Mainly acts as a chloride channel, which mediate uncoupled chloride anion transport in an alternate-access mechanism where a saturable binding site is alternately exposed to either one or the other side of the membrane (PubMed:17673510, PubMed:26801567, PubMed:32818062). Also acts as a DIDS- and thiosulfate- sensitive anion exchanger the exchange of chlori

LOCALIZAÇÃO

Cell membraneEndomembrane system

VIAS BIOLÓGICAS (1)
Inorganic anion exchange by SLC26 transporters
EXPRESSÃO TECIDUAL(Tecido-específico)
Estômago
52.6 TPM
Pulmão
13.4 TPM
Glândula salivar
9.6 TPM
Coração - Átrio
9.3 TPM
Coração - Ventrículo esquerdo
7.2 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:14469UniProt:Q7LBE3
SLC9A3Sodium/hydrogen exchanger 3Modifying germline mutation inRestrito
FUNÇÃO

Plasma membrane Na(+)/H(+) antiporter (PubMed:18829453, PubMed:26358773, PubMed:35613257). Exchanges intracellular H(+) ions for extracellular Na(+) in 1:1 stoichiometry, playing a key role in salt and fluid absorption and pH homeostasis (By similarity). Major apical Na(+)/H(+) exchanger in kidney and intestine playing an important role in renal and intestine Na(+) absorption and blood pressure regulation (PubMed:24622516, PubMed:26358773)

LOCALIZAÇÃO

Apical cell membraneCell membraneRecycling endosome membraneEarly endosome membrane

VIAS BIOLÓGICAS (1)
Sodium/Proton exchangers
MECANISMO DE DOENÇA

Diarrhea 8, secretory sodium, congenital

A disease characterized by watery secretory diarrhea with prenatal onset, prominent abdominal distension after birth due to dilated fluid-filled loops of intestine, elevated fecal sodium concentrations and low urinary sodium concentrations.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
61.0 TPM
Estômago
44.0 TPM
Nervo tibial
37.5 TPM
Intestino delgado
23.2 TPM
Rim - Córtex
16.6 TPM
OUTRAS DOENÇAS (3)
congenital secretory sodium diarrhea 8congenital sodium diarrheacystic fibrosis
HGNC:11073UniProt:P48764
DCTN4Dynactin subunit 4Modifying germline mutation inAltamente restrito
FUNÇÃO

Part of the dynactin complex that activates the molecular motor dynein for ultra-processive transport along microtubules

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, stress fiberCytoplasm, cell cortexCytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (4)
COPI-mediated anterograde transportHSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligandMHC class II antigen presentationCOPI-independent Golgi-to-ER retrograde traffic
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
43.0 TPM
Ovário
41.3 TPM
Fibroblastos
41.2 TPM
Brain Spinal cord cervical c-1
36.6 TPM
Cerebelo
35.8 TPM
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:15518UniProt:Q9UJW0
SERPINA1Alpha-1-antitrypsinModifying germline mutation inTolerante
FUNÇÃO

Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin Reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respira

LOCALIZAÇÃO

SecretedEndoplasmic reticulumSecreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Alpha-1-antitrypsin deficiency

An autosomal recessive disorder characterized by serum levels of alpha-1-antitrypsin below the normal range, and an increased risk for developing pulmonary emphysema and, to a lesser extent, chronic liver disease. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
5944.3 TPM
Sangue
820.2 TPM
Pulmão
194.9 TPM
Rim - Medula
140.0 TPM
Intestino delgado
134.7 TPM
OUTRAS DOENÇAS (3)
alpha 1-antitrypsin deficiencycystic fibrosishemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation
HGNC:8941UniProt:P01009
HMOX1Heme oxygenase 1Modifying germline mutation inTolerante
FUNÇÃO

Catalyzes the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron (PubMed:11121422, PubMed:19556236, PubMed:7703255). Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolize free heme and prevent it from sensitizing cells to undergo apoptosis (PubMed:20055707) (Microbial infection) During SARS-COV-2

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (8)
Cytoprotection by HMOX1Heme degradationIron uptake and transportRegulation of HMOX1 expression and activityHeme signaling
MECANISMO DE DOENÇA

Heme oxygenase 1 deficiency

A disease characterized by impaired stress hematopoiesis, resulting in marked erythrocyte fragmentation and intravascular hemolysis, coagulation abnormalities, endothelial damage, and iron deposition in renal and hepatic tissues. Clinical features include persistent hemolytic anemia, asplenia, nephritis, generalized erythematous rash, growth retardation and hepatomegaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
895.4 TPM
Fibroblastos
185.9 TPM
Ovário
153.0 TPM
Pulmão
133.0 TPM
Skin Sun Exposed Lower leg
110.7 TPM
OUTRAS DOENÇAS (3)
heme oxygenase 1 deficiencycystic fibrosischronic obstructive pulmonary disease
HGNC:5013UniProt:P09601
CEACAM3Cell adhesion molecule CEACAM3Modifying germline mutation inTolerante
FUNÇÃO

Major granulocyte receptor mediating recognition and efficient opsonin-independent phagocytosis of CEACAM-binding microorganisms, including Neissiria, Moxarella and Haemophilus species, thus playing an important role in the clearance of pathogens by the innate immune system. Responsible for RAC1 stimulation in the course of pathogen phagocytosis

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (2)
Cell surface interactions at the vascular wallNeutrophil degranulation
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:1815UniProt:P40198
CEACAM6Cell adhesion molecule CEACAM6Modifying germline mutation inTolerante
FUNÇÃO

Cell surface glycoprotein that plays a role in cell adhesion and tumor progression (PubMed:10910050, PubMed:11590190, PubMed:1378450, PubMed:16204051, PubMed:2022629, PubMed:2803308, PubMed:8776764). Intercellular adhesion occurs in a calcium- and fibronectin-independent manner (PubMed:16204051, PubMed:2022629). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (PubMed:11590190, PubMed:16204051, Pub

LOCALIZAÇÃO

Cell membraneApical cell membraneCell surface

VIAS BIOLÓGICAS (3)
Fibronectin matrix formationCell surface interactions at the vascular wallNeutrophil degranulation
OUTRAS DOENÇAS (1)
cystic fibrosis
HGNC:1818UniProt:P40199

Medicamentos e terapias

LUMACAFTORPhase 4

Mecanismo: Cystic fibrosis transmembrane conductance regulator stabiliser

IVACAFTORPhase 4

Mecanismo: Cystic fibrosis transmembrane conductance regulator positive modulator

TEZACAFTORPhase 4

Mecanismo: Cystic fibrosis transmembrane conductance regulator positive modulator

ATALURENPhase 3

Mecanismo: 80S Ribosome modulator

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

201 variantes patogênicas registradas no ClinVar.

🧬 SLC6A14: GRCh37/hg19 Xq23-28(chrX:113417246-155233731)x1 ()
🧬 SLC6A14: GRCh37/hg19 Xq13.1-27.1(chrX:71017904-140066710)x4 ()
🧬 SLC6A14: GRCh37/hg19 Xq21.33-24(chrX:94003368-117218485)x1 ()
🧬 SLC6A14: GRCh37/hg19 Xq21.32-26.1(chrX:92712119-129831493)x1 ()
🧬 SLC6A14: NC_000023.10:g.(?_113818282)_(115590299_?)del ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 5,440 variantes classificadas pelo ClinVar.

544
2720
2176
Patogênica (10.0%)
VUS (50.0%)
Benigna (40.0%)
VARIANTES MAIS SIGNIFICATIVAS
CFTR: NM_000492.4(CFTR):c.1767-2A>C [Pathogenic]
CFTR: NM_000492.4(CFTR):c.827_828delinsAA (p.Cys276Ter) [Pathogenic]
CFTR: NM_000492.4(CFTR):c.3578T>A (p.Ile1193Asn) [Uncertain significance]
CFTR: NM_000492.4(CFTR):c.1030A>G (p.Ile344Val) [Uncertain significance]
CFTR: NM_000492.4(CFTR):c.744-6_744-4del [Uncertain significance]

Vias biológicas (Reactome)

86 vias biológicas associadas aos genes desta condição.

Amino acid transport across the plasma membrane SLC-mediated transport of neurotransmitters Variant SLC6A14 may confer susceptibility towards obesity FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Neutrophil degranulation FCGR3A-mediated IL10 synthesis ROS and RNS production in phagocytes Metal ion SLC transporters Ion influx/efflux at host-pathogen interface Platelet degranulation Influenza Virus Induced Apoptosis Cell surface interactions at the vascular wall Molecules associated with elastic fibres Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) Syndecan interactions ECM proteoglycans SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer Transcriptional regulation of white adipocyte differentiation UCH proteinases Interleukin-4 and Interleukin-13 signaling RUNX3 regulates CDKN1A transcription Regulation of RUNX3 expression and activity RUNX3 regulates p14-ARF TGFBR3 regulates TGF-beta signaling Peptide ligand-binding receptors G alpha (q) signalling events Signaling by BMP Transcriptional regulation of testis differentiation Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Insulin processing Regulation of insulin secretion Other interleukin signaling Toxicity of botulinum toxin type C (botC) LGI-ADAM interactions Neurexins and neuroligins GABA synthesis, release, reuptake and degradation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Sensory processing of sound by inner hair cells of the cochlea Glutathione conjugation Ca2+ activated K+ channels ABC-family proteins mediated transport RHO GTPases regulate CFTR trafficking Defective CFTR causes cystic fibrosis Ub-specific processing proteases Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis RHOQ GTPase cycle Chaperone Mediated Autophagy Late endosomal microautophagy Aggrephagy Developmental Lineage of Pancreatic Ductal Cells Stimuli-sensing channels Glutathione synthesis and recycling Defective GCLC causes HAGGSD NFE2L2 regulating anti-oxidant/detoxification enzymes Transferrin endocytosis and recycling Inorganic anion exchange by SLC26 transporters Sodium/Proton exchangers MHC class II antigen presentation HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic COPII-mediated vesicle transport Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Cargo concentration in the ER Post-translational protein phosphorylation Heme degradation The NLRP3 inflammasome Iron uptake and transport Purinergic signaling in leishmaniasis infection Cytoprotection by HMOX1 Regulation of HMOX1 expression and activity Heme signaling Fibronectin matrix formation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado3
3Fase 33
2Fase 23
1Fase 14
·Pré-clínico11
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 20 ensaios
✓ Aprovados — podem ser usados hoje
LUMACAFTORIVACAFTORTEZACAFTOR
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Fibrose cística

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06413368 · Maralixibat in Patients With Cystic Fibrosis and Constipatio…Recrutando
PHASE2, PHASE3
NCT00001532 · Role of Genetic Factors in the Development of Lung DiseaseRecrutando
NCT04530383 · Metformin for People With CFRD on CFTR Modulator Therapy to …Recrutando
PHASE2
NCT00943514 · Natural History of BronchiectasisRecrutando
NCT06154447 · Evaluation of VX-828 in Healthy Participants and in Particip…Recrutando
PHASE1
NCT06603246 · A Study to Test the Safety and Effects of Inhaled GDC-6988 i…Recrutando
PHASE1, PHASE2
NCT06995651 · Dorzagliatin in Pancreatic Insufficient Cystic FibrosisRecrutando
PHASE1
NCT07508904 · Exercises' Effect on Muscle Strength, Aerobic Capacity and R…Recrutando
NA
NCT07437105 · Dose Escalation Study Evaluating the Safety and Pharmacokine…Recrutando
PHASE1
NCT05422222 · Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibr…Recrutando
PHASE3
NCT07245407 · A Translational Study for Phenotyping and Endotyping Chinese…Recrutando
NCT06984679 · Physical Impairments in Children With Cystic FibrosisRecrutando
NCT02417740 · Natural History of Noncirrhotic Portal HypertensionRecrutando
NCT05463289 · ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2Recrutando
NA
NCT05668741 · A Phase 1/2 Study of VX-522 in Participants With Cystic Fibr…Recrutando
PHASE1, PHASE2
NCT07484607 · Understanding Inflammation, InFection and Interventions in S…Recrutando
NCT05359991 · Exercise in Child HealthRecrutando
NA
NCT04157361 · Pulmonary Condensate: Non-invasive Evaluation of Pulmonary I…Recrutando
NCT06163482 · Hormonal Responses to a Mixed Meal in People With Cystic Fib…Recrutando
EARLY_PHASE1
NCT06045702 · Establishment of a Primary Epididymal Cell Model From Epidid…Recrutando

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
22.311 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 22.311

#1

Response to modulator therapy in a cystic fibrosis patient with a single identified CFTR variant not eligible for modulator treatment.

The Turkish journal of pediatrics2026 Feb 27

Este artigo relata um caso importante de fibrose cística (FC) onde uma paciente com uma variante rara do gene CFTR (W1282X), inicialmente sem elegibilidade clara para terapia moduladora, obteve melhorias clínicas notáveis. Após apenas um mês de tratamento auto-financiado com elexacaftor/tezacaftor/ivacaftor (ETI), ela demonstrou aumento do FEV1 (12%), redução drástica do cloreto no suor (de 83 para 9 mEq/L) e melhora do IMC, levando à aprovação do tratamento contínuo. Para pacientes e médicos, isso enfatiza a necessidade crucial de facilitar o acesso a terapias moduladoras para variantes raras da FC, pois a resposta clínica na vida real pode ser profundamente benéfica e servir como um forte indicador de eficácia, mesmo quando a elegibilidade inicial ou estudos in vitro não são conclusivos.

🇧🇷 traduzido
#2

Effectiveness of exercise training in people with non-cystic fibrosis bronchiectasis with and without COPD.

Frontiers in rehabilitation sciences2026

Este estudo multicêntrico demonstra que a reabilitação pulmonar, incluindo treinamento de exercícios, melhora significativamente a capacidade de exercício e outros resultados importantes para o paciente (como a redução da falta de ar e fadiga) em pessoas com bronquiectasia não-fibrose cística, seja com ou sem Doença Pulmonar Obstrutiva Crônica (DPOC) concomitante. Os benefícios observados foram equivalentes em ambos os grupos de pacientes, indicando que a reabilitação pulmonar deve ser rotineiramente oferecida a todos com bronquiectasia não-fibrose cística, independentemente da presença de DPOC.

🇧🇷 traduzido
#3

Intestinal Ultrasound Scan in Acute Severe Ulcerative Colitis in children: a multicenter prospective study on behalf of the Porto IBD Working Group of ESPGHAN.

Gastroenterology2026 Mar 16

Este estudo demonstrou que o ultrassom intestinal (USI) é uma ferramenta não invasiva e eficaz para médicos e pacientes pediátricos com colite ulcerativa aguda grave. Ele pode prever precocemente quais crianças não responderão à terapia inicial com corticosteroides, indicando a necessidade de tratamentos mais avançados, como medicamentos biológicos ou cirurgia, e permitindo decisões mais rápidas e personalizadas para otimizar o cuidado.

🇧🇷 traduzido
#4

Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation.

Cell reports. Medicine2026 Mar 17

Este artigo revela que um defeito genético no receptor FPR1 compromete a vigilância imunológica, aumentando o risco de cânceres epiteliais. No entanto, descobriu-se que inibidores da proteína MAPK p38α podem corrigir essa falha, restaurando a função das células imunológicas e melhorando a resposta a tratamentos de câncer em modelos animais, além de prevenir o desenvolvimento acelerado de câncer colorretal. Isso sugere uma promissora nova estratégia para prevenir e tratar certos tipos de câncer em pacientes com essa mutação. *É importante notar que o resumo fornecido não menciona Fibrose Cística; o foco é na relação entre FPR1, imunidade e câncer.*

🇧🇷 traduzido
#5

Interkingdom signaling elicited by bacterial extracellular vesicles in human cystic fibrosis airway epithelium and neutrophils.

Frontiers in cellular and infection microbiology2026

Este estudo revelou que nos pulmões de pacientes com fibrose cística (FC), bactérias como a *Pseudomonas aeruginosa* e as células humanas (epitélio e neutrófilos) se comunicam ativamente através de pequenas "bolhas" chamadas vesículas extracelulares (EVs). As EVs bacterianas impactam diretamente a resposta das células dos pacientes, afetando a liberação de suas próprias EVs e o comportamento dos neutrófilos, que são cruciais na inflamação. Compreender essa comunicação é fundamental para que médicos e pacientes possam desenvolver novas estratégias para controlar as infecções crônicas e a inflamação pulmonar na FC.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC36.875 artigos no totalmostrando 194

2026

Advanced Lung Cancer Inflammation Index (ALI) as an Independent Predictor for Bronchiectasis Exacerbation Risks.

Journal of inflammation research
2026

Jugular Vein Occlusion-Induced Intracranial Hypertension Mimicking Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator-Associated Intracranial Hypertension: A Diagnostic Pitfall.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2026

Microbial signatures and host immune responses associated with the development of ventilator-associated pneumonia among patients with neurological injuries.

Microbiology spectrum
2026

Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1.

JCI insight
2026

Effectiveness of exercise training in people with non-cystic fibrosis bronchiectasis with and without COPD.

Frontiers in rehabilitation sciences
2026

Development of CpG-Depleted CFTR Plasmid-Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease.

The journal of gene medicine
2026

Inhalable gene and RNA therapy for cystic fibrosis: perspectives and progress in clinical development.

Nanomedicine (London, England)
2026

Iloprost-loaded inhalable Nano into Micro (NiM) formulations for treating hyper-inflammation in a pre-clinical model of cystic fibrosis airway epithelial cells.

Drug delivery and translational research
2026

Recalibration: Exploring the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Self-Concept for Adults with Cystic Fibrosis.

The patient
2026

Colistin-stabilized antisolvent precipitation enables engineering of microcrystalline niclosamide for inhalable composite powders.

International journal of pharmaceutics
2026

Genome-wide association study reveals two novel genetic loci associated with chronic lung allograft dysfunction.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
2026

Evaluation of the methodology of independent Community Advisory Boards in health products research and development: a mixed-methods cross-sectional survey study.

Research involvement and engagement
2026

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Changes to serum lipids, BMI and body composition in adults with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI): A scoping review.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Apical hyperosmotic challenge upregulates aquaporin-3 in human airway epithelia.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Rhinovirus Infection Promotes Suppression of Sphingosine and Enhanced Bacterial Infection in Cystic Fibrosis Airways.

The Journal of biological chemistry
2026

The challenges of detecting neutrophil CFTR.

Journal of innate immunity
2026

One Size May Not Fit All: A Case Series.

Pediatric pulmonology
2026

Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.

Open forum infectious diseases
2026

Bowel preparation for colonoscopy in children: a survey of the Italian society of pediatric gastroenterology, hepatology and nutrition.

Italian journal of pediatrics
2026

Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

[Allergic bronchopulmonary aspergillosis in internal medicine].

La Revue de medecine interne
2026

Validity of Alfred Step Test Exercise Protocol (A-STEP) as a Surrogate VO2Max Cardiopulmonary Exercise Test (CPET) to Cycle Ergometry in Adults With Cystic Fibrosis.

Canadian respiratory journal
2026

Hyperammonemia syndrome due to Pluralibacter gergoviae bacteremia in an immunocompromised patient: case report.

ASM case reports
2026

Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Documentation practices of cystic fibrosis (CF) pharmacists: An opportunity for discipline-wide quality improvement.

Journal of the American Pharmacists Association : JAPhA
2026

Intestinal Ultrasound Scan in Acute Severe Ulcerative Colitis in children: a multicenter prospective study on behalf of the Porto IBD Working Group of ESPGHAN.

Gastroenterology
2026

Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation.

Cell reports. Medicine
2026

Harnessing metabolomics and proteomics in a clinical trial for pulmonary arterial hypertension: insights from post-hoc analysis of the REHAB-PH trial.

EBioMedicine
2026

Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis.

Advances in therapy
2026

[Transition and transfer from pediatrics to adult medicine].

Wiener medizinische Wochenschrift (1946)
2026

Bioengineered 3D hPSC-Cholangiocyte Ducts With Physiological Signals for Biliary Disease Modeling.

Advanced healthcare materials
2026

Global Collaboration in Cystic Fibrosis: Lessons From the COVID-19 Pandemic for Low- and Middle-Income Countries.

Pediatric pulmonology
2026

Interkingdom signaling elicited by bacterial extracellular vesicles in human cystic fibrosis airway epithelium and neutrophils.

Frontiers in cellular and infection microbiology
2026

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry.

ERJ open research
2026

Clinical profile and in-hospital outcomes of patients hospitalised for bronchiectasis exacerbation.

ERJ open research
2026

Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2026

Advancements in Sweat Testing Techniques for Cystic Fibrosis: From Classical to Novel Methods.

Pediatric pulmonology
2026

The Human Cost of Respiratory Care: Professional Quality of Life and Burnout across Multidisciplinary Cystic Fibrosis Teams.

Chest
2026

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension study.

Annals of the American Thoracic Society
2026

N-acetylglucosamine utilization and impact on antibiotic susceptibility, oxidative stress tolerance, and swimming in Stenotrophomonas maltophilia.

Microbiology spectrum
2026

Complete genome sequences of Pseudomonas aeruginosa clone C strains 8277, PT31M, and SG50M isolated from the urinary tract and anthropogenic water environments.

Microbiology resource announcements
2026

Renal Function Decline in Adults with Cystic Fibrosis Experiencing Pulmonary Exacerbations.

Annals of the American Thoracic Society
2026

Beta cell function and insulin sensitivity during elexacaftor/tezacaftor/ivacaftor therapy in people with cystic fibrosis.

Frontiers in endocrinology
2026

The natural human adaptive IgG-specific immune response is skewed towards non-protective tail domains of DNABII proteins.

Frontiers in immunology
2026

Development and Validation of an Electronic Health Record Algorithm to Predict the Presence of Chronic Obstructive Pulmonary Disease.

International journal of chronic obstructive pulmonary disease
2026

Research Progress on the Mechanisms of High Mucus Secretion in the Airway: A Scoping Review.

International journal of chronic obstructive pulmonary disease
2026

Stopping an outbreak of Pseudomonas aeruginosa ST111 by temporarily blocking the siphon to disinfect it before the transition to the wastewater drain.

GMS hygiene and infection control
2026

Capsaicinoids prevent intestinal fluid secretion and motility by inhibiting chloride channels.

Journal of ethnopharmacology
2026

Mucus and inflammation in the HEMT Era: Persistent barriers to complete airway normalization in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Relationships between lung ultrasound, chest CT, and echocardiographic findings in children with bronchopulmonary dysplasia: A multimodal imaging study.

Respiratory medicine
2026

Current State of Clinical Care of People With Cystic Fibrosis.

Pharmacotherapy
2026

Density fluctuations of Burkholderia and Achromobacter in cystic fibrosis sputum.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Fetal Transplacental Therapy to Mitigate Consequences of Cystic Fibrosis.

Clinical therapeutics
2026

Determining the Minimal Clinically Important Difference of the 40-Item Smell Identification Test in People With Cystic Fibrosis.

International forum of allergy &amp; rhinology
2026

Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis.

Nutrients
2026

Early Life Nutrition: The First 1000 Days and Healthy Aging in Cystic Fibrosis.

Nutrients
2026

A Diagnostic Dilemma: Concurrent Diagnosis of Cystic Fibrosis and Definitive Kabuki Syndrome Type 1.

International journal of molecular sciences
2026

Antenatal CFTR Modulators to Treat a Healthy Pregnant Woman with a Fetus Affected by Cystic Fibrosis Complicated by Meconium Ileus and Intestinal Volvulus: From a Suspicion of the Disease to a Targeted Treatment in Utero: Case Report and Narrative Review.

Journal of clinical medicine
2026

Cerebral Desaturation in Cystic Fibrosis Patients Undergoing Double Lung Transplantation.

Respiratory medicine
2025

Optimizing Reproductive Autonomy in Cystic Fibrosis: The Role of Oocyte Cryopreservation.

Journal of reproduction &amp; infertility
2026

The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial.

Transplant international : official journal of the European Society for Organ Transplantation
2026

Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report.

Respirology case reports
2026

Brachial artery flow-mediated dilation is less repeatable in children with a chronic inflammatory disease compared to their healthy peers.

Clinical physiology and functional imaging
2026

Effect of an airway clearance technique on nebulized drug delivery in patients with CF: A randomized cross-over trial.

Physiotherapy
2026

Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Association of proteins involved in fetal lung development with respiratory outcomes in infancy.

Respiratory medicine
2026

Evidence of sex-related differences in vascular health among people with cystic fibrosis.

Respiratory medicine
2026

Innovative methodologies for elucidating bushfire smoke-induced pathophysiological mechanism.

The Science of the total environment
2026

Draft genome sequences of 109 gut bacteria isolated from colonoscopy samples of individuals with and without cystic fibrosis.

Microbiology resource announcements
2026

Hypochloremic Hypokalemic Metabolic Alkalosis as a Manifestation of CFTR-Related Disorder.

Pediatric pulmonology
2026

Etiologies of chronic cough in children: a two-year experience from a tertiary pediatric pulmonology center.

Turkish journal of medical sciences
2026

[Evolution of thoracic computed tomography after therapy with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis].

Revue medicale de Liege
2026

Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators.

Acta paediatrica (Oslo, Norway : 1992)
2026

CRISPR-Cas9 genome editing in the parental iPSC line PCIi033-A to introduce the homozygous mutation p.F508del (c.1521_1523del) in the CFTR gene.

Stem cell research
2026

The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Discussing the potential health impacts of carrying a single CF-causing CFTR mutation during consult with people with CF who are planning a pregnancy.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Year in review: "Best" papers in pediatric pulmonary and sleep medicine in 2025.

Paediatric respiratory reviews
2026

Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients.

Pulmonary pharmacology &amp; therapeutics
2026

Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis.

Pulmonary therapy
2026

The interplay between temperature and growth phase shapes the transcriptional landscape of Pseudomonas aeruginosa.

Journal of bacteriology
2026

Mechanisms of thermoregulation in Pseudomonas aeruginosa.

Journal of bacteriology
2026

Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS.

Frontiers in medicine
2026

Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease.

World journal of gastroenterology
2026

Untargeted Metabolomic and Lipidomic Profiling in Cystic Fibrosis Patients Using UPLC-QTOF-MS.

Journal of proteome research
2026

Genetic and clinical characteristics of pediatric patients with cystic fibrosis: a single-center retrospective study in China.

Orphanet journal of rare diseases
2026

Adherence to guidelines, pitfalls, and emerging technologies in endoscopic practice for celiac disease: a nationwide SIGENP survey.

European journal of pediatrics
2026

Single-cell RNAseq identifies persistent epithelial and immune dysfunction in PwCF by mitigating inter-individual sampling heterogeneity.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Integrating cognitive behavioral therapy into specialty care for adolescents with cystic fibrosis: a feasibility trial.

Journal of pediatric psychology
2026

Organoids for Metabolic Disease Modeling.

Journal of inherited metabolic disease
2026

CFTR Modulators in Brazil: Not for Everyone-A Comparison of Ineligibility Across Different Regions.

Pediatric pulmonology
2026

Advancing Mental Healthcare for Individuals With Cystic Fibrosis in Low- and Middle-Income Countries.

Pediatric pulmonology
2026

Loss of Potassium and Chloride Transport Changes PM-Induced Epithelial Dysfunction.

Journal of inflammation research
2026

'The Hero's journey': Narratives on the transition to motherhood with cystic fibrosis.

British journal of health psychology
2026

A longitudinal evaluation of localised chronic Pseudomonas aeruginosa infection in cystic fibrosis rat models.

BMC microbiology
2026

Multiple virulence attenuating strategies against Pseudomonas aeruginosa: Natural, synthetic, and synergistic approaches.

World journal of microbiology &amp; biotechnology
2026

Transcriptional regulation of the pneumococcal capsule can dictate serotype-specific infection.

Nature communications
2026

Gegen Qinlian decoction alleviates bacterial diarrhea via Lactobacillus amylovorus-modulated restoration of colonic water transport through the cAMP/CFTR/AQP3 pathway.

Microbial pathogenesis
2026

mSphere of Influence: Rethinking microbial identity through variability.

mSphere
2026

Glycoside hydrolases enhance antibiotic activity against Pseudomonas aeruginosa biofilms from cystic fibrosis airways.

Microbiology spectrum
2026

Co-Design of a Novel Telehealth Exercise Model of Care for Adults With Cystic Fibrosis.

Pediatric pulmonology
2026

Contemporary outcomes of isolated liver and combined liver-lung transplantation for cystic fibrosis in children.

Journal of pediatric gastroenterology and nutrition
2026

Burkholderia cepacia Bacteremia Complicated by Acute Parotid Abscess in a Poorly Controlled Diabetic Patient With Community-Acquired Pneumonia: A Case Report.

Cureus
2026

Disparities in Access to Cystic Fibrosis Therapy Across Countries.

Pediatric pulmonology
2026

KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma.

Oncoimmunology
2026

CFTR knock-out mice exhibit impaired renal compensation to dietary NaCl depletion.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy.

Pediatric pulmonology
2026

MLPA-Detected CFTR Exon Deletions in Children With Inconclusive CFTR Sequencing: A Single-Center Experience From Türkiye.

Pediatric pulmonology
2026

Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report.

Journal of diabetes science and technology
2026

Peripheral muscle oxygenation during upper extremity functional exercise and balance in pediatric patients with cystic fibrosis: a cross-sectional study.

European journal of applied physiology
2026

Outcomes of Kidney Transplantation in Cystic Fibrosis.

Transplantation proceedings
2026

CFTR modulators-induced acne: Case series and analysis of pharmacovigilance databases.

Annales de dermatologie et de venereologie
2026

Qualitative analysis of genomic mutations and antibiotic susceptibility testing of Pseudomonas aeruginosa isolates from chronic lung infections.

PloS one
2026

Craniofacial development in children with cystic fibrosis.

American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
2026

Bacterial EVs contain small RNAs and transfer RNAs that regulate inflammation in lung infections.

Frontiers in immunology
2026

Therapies for bronchiectasis: mechanisms and potential effects.

Frontiers in immunology
2026

Urinary System Involvement in Children With Cystic Fibrosis: A Single-Center Retrospective Cohort.

Pediatric pulmonology
2026

Assessing the reversibility of bronchiectasis with deep learning - Authors' reply.

The Lancet. Respiratory medicine
2026

Assessing the reversibility of bronchiectasis with deep learning.

The Lancet. Respiratory medicine
2026

Identification of CD164 as an essential entry receptor for divergent adeno-associated viruses.

Proceedings of the National Academy of Sciences of the United States of America
2026

Pseudomonas aeruginosa gene expression changes during established biofilm infection in a cystic fibrosis lung model.

Microbiology (Reading, England)
2026

WTC 2025 Highlights: Infectious Disease.

Transplantation
2026

Longitudinal observation of severe asthma comorbidities and oral corticosteroids use from SANI and ISAR registries.

The World Allergy Organization journal
2026

Sex Differences in Muscle-Respiratory Function Relationship in Lung Transplant Patients: A Longitudinal Study.

Journal of cachexia, sarcopenia and muscle
2026

Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network.

BMC pulmonary medicine
2026

Predicting pulmonary exacerbations in cystic fibrosis subpopulations and implications for clinical trial design.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Cystic fibrosis year in review 2025.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Neutralization of acyl-CoA-binding protein attenuates glucocorticoid-mediated suppression of cancer immunosurveillance.

Proceedings of the National Academy of Sciences of the United States of America
2026

Functional analysis of purM in Burkholderia cenocepacia using a trimethoprim-selectable allelic exchange and mini-Tn7 complementation approach.

Microbiology spectrum
2026

Epithelial plasma membrane transporters as drug targets.

Physiological reviews
2026

When Recurrent Pancreatitis Is Not Pancreatitis: Cyclic Vomiting Syndrome Masquerading as Acute Pancreatitis in a Young Adult.

Cureus
2026

ERS Congress 2025: highlights from the Respiratory Infections Assembly.

ERJ open research
2026

CFTR activity in nasal potential difference of adults with idiopathic bronchiectasis.

Respiratory research
2026

Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Clinical and epidemiological characteristics of nontuberculous mycobacteria pulmonary infections in the healthcare area of Virgen del Rocío University Hospital in Seville (2020-2023).

Enfermedades infecciosas y microbiologia clinica (English ed.)
2026

Ultraprocessed Food Consumption and Behavioral Outcomes in Canadian Children.

JAMA network open
2026

Implementing Genomic Medicine in Primary Care: A Convergent Mixed Method Case Study.

Journal of evaluation in clinical practice
2026

Aquagenic Wrinkling of the Palms as a Screening Indicator for Cystic Fibrosis Beyond Infancy.

Cureus
2026

A Narrative Review of Gene-Environment Interactions in Pediatric Pulmonology.

Pediatric pulmonology
2026

Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis.

Journal of medical ethics
2026

Lipopolysaccharide-targeting treatments for multidrug-resistant Pseudomonas aeruginosa.

Expert opinion on therapeutic targets
2026

Towards functional precision medicine? Evidence standards of organoids as patient-specific models.

History and philosophy of the life sciences
2026

Phage isolation and functional characterization reveal strong antibiofilm activity against Pseudomonas aeruginosa in a cystic fibrosis sputum model.

Frontiers in cellular and infection microbiology
2026

Pseudomonas aeruginosa Biofilms in Cystic Fibrosis: Interactions, Methods, and Therapeutic Strategies.

BioMed research international
2026

Feasibility of electrical impedance tomography-guided PEP in children with CF and TBM.

Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR
2026

Unraveling the Complexities of Kartagener's Syndrome: A Case of Bronchiectasis, Isolated Dextrocardia, and Primary Ciliary Dyskinesia in an Adult With Chronic Respiratory Symptoms.

Clinical case reports
2026

[MUC1 and SIGIRR as Negative Regulators of TLR Signaling: Expression, Function, and Anti-inflammatory Augmentation].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
2026

Prolactin signaling in the highly osmotolerant Mozambique tilapia, Oreochromis mossambicus.

General and comparative endocrinology
2026

Opportunistic thoracic CT scan over bone densitometry in CF care: Is it possible to screen for osteoporosis using a CT scan?

Respiratory medicine
2026

Effect of vanzacaftor/tezacaftor/ivacaftor on cystic fibrosis nasal epithelial cells and intestinal organoids compared to elexacaftor/tezacaftor/ivacaftor.

Respiratory medicine
2026

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR-DRP1 modulation.

Cell death discovery
2026

[Hearing impairment in children with cystic fibrosis].

Vestnik otorinolaringologii
2026

In Utero CFTR Modulator Therapy in Fetuses With Cystic Fibrosis.

NeoReviews
2026

L-ascorbic acid exerts anti-microbial and anti-virulence effects against multi-drug resistant Burkholderia cepacia complex.

Microbial pathogenesis
2026

Genetic strategies for negative or variant of uncertain significance findings in exome sequencing in hereditary bronchiectasis: a case series.

Therapeutic advances in respiratory disease
2026

Large variations in total and allele-specific transcript expression in a disease mutation-independent manner.

Scientific reports
2026

Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.

Nature communications
2026

The effectiveness and value of brensocatib for the treatment of non-cystic fibrosis bronchiectasis.

Journal of managed care &amp; specialty pharmacy
2026

Successful Management of Chronic Achromobacter xylosoxidans Bronchial Infection With Nebulized Levofloxacin in a Patient With Non-cystic Fibrosis Bronchiectasis.

Archivos de bronconeumologia
2026

Different States of Lung Allograft Injury Assessed by Plasma Donor-Derived and Total Cell-Free DNA.

The Journal of molecular diagnostics : JMD
2026

Does it matter how cystic fibrosis transmembrane conductance regulator modulators reduce inflammation in cystic fibrosis?

Annals of the American Thoracic Society
2026

A state of the union on alpha-1 antitrypsin deficiency at the Veterans Health Administration.

Annals of the American Thoracic Society
2026

Activation of farnesoid X receptor inhibits TMEM16A-mediated chloride secretion in renal collecting duct cells and retards renal cyst progression.

American journal of physiology. Renal physiology
2026

Deciphering microbial biofilm: mechanism, infection, and advanced approaches for control.

Folia microbiologica
2026

Uncovering Cystic Fibrosis Carrier: Insights From a Heterozygous CFTR-F508del Rabbit Model.

International forum of allergy &amp; rhinology
2026

The regional landscape of the human colon culturome in health and cystic fibrosis.

Microbiology spectrum
2026

Streptococcus sanguinis antagonizes Prevotella melaninogenica in the context of the cystic fibrosis respiratory microbiome.

Journal of bacteriology
2026

Normal Values for Respiratory Oscillometry in Pediatrics: An Argument for a Local Control Population.

Pediatric pulmonology
2026

Parental Experiences and Coping Strategies of Families Caring for a Child With Cystic Fibrosis.

Pediatric pulmonology
2026

Challenges and Practical Solutions in the Management of Cystic Fibrosis in Resource-Limited Countries: The Indian Experience.

Pediatric pulmonology
2026

The archaic CUP pilus SMF-1 utilizes a specific antiparallel bundling mechanism to initiate biofilm formation.

bioRxiv : the preprint server for biology
2026

Lung retransplantation after initial single lung transplantation.

JHLT open
2026

"No Words for Feelings": Alexithymia in Children With Cystic Fibrosis and Their Caregivers.

Pediatric pulmonology
2026

The Relationship Between Peripheral Eosinophilia, Lower Respiratory Tract Pathogens, Age at First Pneumonia, and Malnutrition in Children with Non-cystic Fibrosis Bronchiectasis.

Thoracic research and practice
2026

Inhaled Antibiotic and Biologic Formulations Targeting Pseudomonas aeruginosa.

Pharmaceutics
2026

Recent Advances in Inhalation Therapy: An Overview.

Pharmaceuticals (Basel, Switzerland)
2026

Biofilm Formation in Aspergillus fumigatus: A Comparative Study of Strains from Different Origins.

Microorganisms
2026

From Promise to Practice: Harmonizing Telemedicine in Pediatric Chronic Respiratory Diseases.

Journal of clinical medicine
2026

Cystic Fibrosis: A Disease with a New Face.

Life (Basel, Switzerland)
2026

The Prognostic Significance of Bronchoalveolar Lavage Cellular Analysis in Evaluating Disease Burden in Non-Cystic Fibrosis Bronchiectasis.

Life (Basel, Switzerland)
2026

Restoration of Defective CFTR in Human Nasal Respiratory Epithelial Cells by CFTR Modulators and mRNA Transfection.

International journal of molecular sciences
2026

Special Issue "Inflammatory Airway Diseases: Diagnosis, Pathology, Molecular Mechanisms and Treatment Options".

International journal of molecular sciences
2026

Phage-Based Approaches to Chronic Pseudomonas aeruginosa Lung Infection in Cystic Fibrosis.

Antibiotics (Basel, Switzerland)
2026

Simulation-Driven Annotation-Free Deep Learning for Automated Detection and Segmentation of Airway Mucus Plugs on Non-Contrast CT Images.

Bioengineering (Basel, Switzerland)
2026

Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study.

Children (Basel, Switzerland)
2026

Cystic fibrosis-related diabetes is associated with reduced airway microbial diversity.

Respiratory research
2026

Kidney care at NICU discharge and follow-up recommendations for preterm infants<34 weeks.

Journal of perinatology : official journal of the California Perinatal Association
2026

Alterations of bile acid composition in children with cystic fibrosis compared to healthy controls.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2026

Novel translational pulmonary MRI in pediatrics: A Review of the last 10 years.

The European respiratory journal
2026

Pathology of the Human Temporal Bone in a Rare Case of Combined Usher Syndrome and Cystic Fibrosis.

Otology &amp; neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
2026

Role of Iron Availability in Modulating Pseudomonas aeruginosa's Antifungal Effects on Planktonic and Biofilm Growth of Scedosporium/Lomentospora Under Cystic Fibrosis-Mimicking Conditions.

Journal of fungi (Basel, Switzerland)
2026

Metabolic Syndrome Predisposes Ossabaw Minipig Retina to an Early Neurodegenerative Milieu.

Cells
2026

Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis.

Biology
2026

Towards accurate artificial intelligence models for strain-level phage-host prediction.

Briefings in bioinformatics
Ver todos os 36.875 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Associação brasileira dedicada a Doenças raras (geral).

Instituto nacional que coordena e lista associações regionais de fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Associação brasileira dedicada a Fibrose cística.

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Fibrose cística

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Response to modulator therapy in a cystic fibrosis patient with a single identified CFTR variant not eligible for modulator treatment.
    The Turkish journal of pediatrics· 2026· PMID 41871565mais citado
  2. Effectiveness of exercise training in people with non-cystic fibrosis bronchiectasis with and without COPD.
    Frontiers in rehabilitation sciences· 2026· PMID 41868961mais citado
  3. Intestinal Ultrasound Scan in Acute Severe Ulcerative Colitis in children: a multicenter prospective study on behalf of the Porto IBD Working Group of ESPGHAN.
    Gastroenterology· 2026· PMID 41850540mais citado
  4. Inhibition of MAPK p38&#x3b1; overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation.
    Cell reports. Medicine· 2026· PMID 41850246mais citado
  5. Interkingdom signaling elicited by bacterial extracellular vesicles in human cystic fibrosis airway epithelium and neutrophils.
    Frontiers in cellular and infection microbiology· 2026· PMID 41847442mais citado
  6. Optimizing cystic fibrosis-related diabetes screening in adults using the oral glucose tolerance test (OGTT): a single center mixed methods study.
    JBI Evid Implement· 2026· PMID 41995275recente
  7. Predictors of quality of life in parents of children with rare diseases: a tertiary care center cross-sectional study in Saudi Arabia.
    Front Public Health· 2026· PMID 41994538recente
  8. Polymicrobial extracellular vesicles reduce the innate immune response of human cystic fibrosis bronchial epithelial cells.
    bioRxiv· 2026· PMID 41993502recente
  9. Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review.
    Front Drug Deliv· 2026· PMID 41993129recente
  10. Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.
    Adv Ther· 2026· PMID 41991874recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:586(Orphanet)
  2. OMIM OMIM:219700(OMIM)
  3. MONDO:0009061(MONDO)
  4. Fibrose Cistica(PCDT · Ministério da Saúde)
  5. GARD:6233(GARD (NIH))
  6. Variantes catalogadas(ClinVar)
  7. Busca completa no PubMed(PubMed)
  8. Artigo Wikipedia(Wikipedia)
  9. Q178194(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Fibrose cística
Compêndio · Raras BR

Fibrose cística

ORPHA:586 · MONDO:0009061
🇧🇷 Brasil SUS
Triagem
IRT (Tripsina Imunorreativa) em sangue seco
PNTN
Fase 1 · Nacional
Incidência BR
1:7.500
CEAF
1AAlfadornaseTobramicina inalatóriaIvacaftorLumacaftor/Ivacaftor+2 mais
Internações
3.245/ano
Prevalência BR
1:7500
Custo SUS
R$ 8.920/internação
Dados
DATASUS 2024
Geral
Prevalência
1-5 / 10 000
Herança
Autosomal recessive
CID-10
E84.0 · Fibrose cística com manifestações pulmonares
CID-11
Ensaios
30 ativos
Medicamentos
4 registrados
Início
All ages
Prevalência
11.1319 (Europe)
MedGen
UMLS
C0010674
Repurposing
5 candidatos
atalurenCFTR channel agonist|dystrophin stimulant
finafloxacinbacterial DNA gyrase inhibitor
ivacaftorCFTR channel potentiator
+2 outros
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades